Vimarsana
Biggest News Aggregation in the World

Page 6 - Open Angle Glaucoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Open Angle Glaucoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Open Angle Glaucoma Today - Breaking & Trending Today

Anti Glaucoma Therapy in a Tertiary Hospital in Ghana - Vimarsana News

Anti Glaucoma Therapy in a Tertiary Hospital in Ghana

Efforts to understand more about the magnitude and distribution of glaucoma in Africa have usually been limited by reliance on clinic populations and inadequate definitions of glaucoma. Nonetheless, the surveys indicate that OAG is an important cause of blindness in Africa. The early stages of both types of glaucoma are often asymptomatic so patients often present late, particularly in developing countries. The challenges are with late presentation for diverse reasons one of which is low awareness and the silent nature of the disease. In Ghana, 19.4% of blindness is due to glaucoma. The preva...

SPARC reports positive results from Phase 3 trial for its investigational ophthalmic suspension - Vimarsana News

SPARC reports positive results from Phase 3 trial for its investigational ophthalmic suspension

Sun Pharma Advanced Research Company today reported positive top-line results from its Phase 3 trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of Open Angle Glaucoma or Ocular Hypertension. The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day. PDP-716 is a novel, once daily, ophthalmic suspension of Brimonidine Tartrate 0.35%. PDP-716 is developed using SPARC's proprietary TearActTM technology. Powered by Capital Market - Live News (This story has n...

Glioblastoma Pipeline Analysis: 60+ Key Pipeline Therapies and 60+ Key Pharma Players are Looking Out in the Glioblastoma Pipeline Landscape - Vimarsana News

Glioblastoma Pipeline Analysis: 60+ Key Pipeline Therapies and 60+ Key Pharma Players are Looking Out in the Glioblastoma Pipeline Landscape

Glioblastoma Pipeline Analysis: 60+ Key Pipeline Therapies and 60+ Key Pharma Players are Looking Out in the Glioblastoma Pipeline Landscape iCrowd Newswire DelveInsight's Glioblastoma Pipeline Insight report offers a detailed overview of the pipeline therapies that are in various clinical and preclinical stages of growth, as well as their launch and how the market is expected to change as a result across the Glioblastoma domain. For Glioblastoma emerging drugs, the Glioblastoma Pipeline Analysis report provides a 360° view of the therapeutics landscape by development point, product type, ro...

Awareness sessions on 'sneak thief of sight' - Vimarsana News

Awareness sessions on 'sneak thief of sight'

Opthalmologists in Hyderabad to observe Glaucoma Week from today

Erectile dysfunction? Your eye drop might be responsible! - Vimarsana News

Erectile dysfunction? Your eye drop might be responsible!

Punch Newspapers Sections Lara Adejoro Vice-President, Ophthalmological Society of Nigeria and Consultant Ophthalmologist at The Eye Doctors Clinic, Dr. Abiola Oyeleye, says some glaucoma eye drops can ‘minimally increase’ the incidence of sexual dysfunction and impotence. He, however, added that the benefits of the eye drops far outweigh the consideration of not using them. Oyeleye spoke in reaction to a study published by the National Centre for Biotechnology Information on the correlation in severity between glaucoma and erectile dysfunction. The study states that there is a positive a...